Due to the fact that MAPK1 was the most prominent target in the core component-target-pathway network, we concluded that MAPK1, IL6, AKT1, VEGFA, EGFR, and TP53 were the core targets of UR-AP against HT. The gene discussed is MAPK1; the disease is hematocrit.